LLY
Eli Lilly and Company
LLY has the edge over USPH overall, supported by stronger fundamentals and stronger modeled upside.
USPH
U.S. Physical Therapy, Inc.
USPH's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
USPH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Stable |
USPH's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
USPH PE Valuation
USPH has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over USPH on the outlook, with more favorable profitability expectations.
USPH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for USPH, with profitability holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus USPH up 38%.
USPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.22 | +35% |
| Q3 2023 | $1.72 | -42% |
| Q2 2023 | $1.93 | -34% |
| Q1 2023 | $2.16 | -25% |
| Q4 2022 | $2.25 | -6.6% |
| Q3 2022 | $2.98 | +26% |
| Q2 2022 | $2.92 | +26% |
| Q1 2022 | $2.87 | +15% |
| Q4 2021 | $2.41 | -2.8% |
USPH earned $2.38 per share over the past year, up 38% from the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over USPH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over USPH on profitability, with a higher operating margin.
USPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $222.6M | +13% |
| Q2 2026 | $214.1M | +8.5% |
| Q1 2026 | $198.3M | +7.9% |
| Q4 2025 | $202.7M | +12% |
| Q3 2025 | $197.1M | +17% |
| Q2 2025 | $197.3M | +18% |
| Q1 2025 | $183.8M | +18% |
| Q4 2024 | $180.4M | +17% |
USPH's revenue has grown year over year for 22 quarters in a row: $223M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | -1.6 points |
| Q2 2026 | 10% | -2.4 points |
| Q1 2026 | 6.3% | -4.4 points |
| Q4 2025 | 8.3% | +0.2 points |
| Q3 2025 | 13% | +4.1 points |
| Q2 2025 | 13% | +0.9 points |
| Q1 2025 | 11% | +1.5 points |
| Q4 2024 | 8.1% | +8.6 points |
USPH's operating margin was 11% last quarter, down 1.6 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over USPH on cash flow, with more consistent year-over-year improvement.
USPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $20.7M | +32% |
| Q2 2026 | $29M | -8.2% |
| Q1 2026 | -$1.6M | +$5.7M |
| Q4 2025 | $21M | +24% |
| Q3 2025 | $15.6M | -20% |
| Q2 2025 | $31.6M | +19% |
| Q1 2025 | -$7.3M | -381% |
| Q4 2024 | $16.9M | -31% |
USPH generated $69M in free cash flow over the past year, up 21% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
USPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -142K shares |
| 1 year | -1.8% | -276K shares |
| 3 years | -0.4% | -59K shares |
| 5 years | +16% | +2M shares |
| Available history | +17% | +2.2M shares |
USPH has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over USPH on leverage, with a lower net debt burden relative to earnings.
USPH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.0x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.4x | Healthy |
USPH's net debt is about 2.1 years of its operating earnings (EBITDA), up from 1.2 years a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
USPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 72.9 | Overbought |
| Stochastic | 86.8 | Overbought |
USPH's weekly RSI is 73 (overbought) and its Stochastic is 87 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
USPH PE vs Healthcare Sector
| Metric | USPH | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
USPH has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
USPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $88.9 | 11% above |
| 20 week MA | $82.1 | 20% above |
| 50 week MA | $78.1 | 26% above |
| 100 week MA | $79.1 | 25% above |
| 200 week MA | $88.4 | 12% above |
USPH has climbed back above all five of its weekly moving averages, and it's now 12% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over USPH on returns for 2026, with the stronger performance.
USPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $114.0 | $120.9 | +6% |
| 2021 | $120.9 | $95.7 | -21% |
| 2022 | $95.7 | $81.4 | -15% |
| 2023 | $81.4 | $93.1 | +14% |
| 2024 | $93.1 | $90.9 | -2.4% |
| 2025 | $90.9 | $81.0 | -11% |
| 2026 YTD | $81.0 | $98.6 | +22% |
USPH has finished lower in four of the last six years. It's up 22% so far in 2026.